Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study

HaEmek Medical Center, Israel

Status: Unknown

Conditions: Sickle Cell β+ or β0 Thalassemia; Sickle Cell Anemia

Study type: Observational

Funder types: Other

Identifiers

NCT01905787

0128-11-EMC

Details and patient eligibility

About

The purpose of this study is to take advance of the presence of two different cohorts of SCA patients in one country, the first group included SCA patients from Bedouin Arab origin that lives in Israel for more than one century and originally comes from African countries or Saudi Arabia, those patients lives in north east Israel and are treated at the Hematology Unit of the Emek Medical Center, the second group are SCA patients from African origin that come to Israel in the last decades and belong to original African population, this group receive treatment at the Pediatric Hematology Unit, Dana Children's Hospital, Ichilov Medical Center. A third group is a cohort of SCA patients treated at Schneider Children's Hospital Hematology Unit. Those patients belong also to the Israel Arab population and patients from a village that African Muslims live for many years. The characteristics of the three groups will be compared to the characteristics of a fourth group, a cohort of Afro-American SCA patients that are followed up and treated at the Pediatric Hematology Unit, Detroit Children's Medical Center, Detroit, Michigan, USA.

Full description

Group 1 - Emek group - (EMC): 100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).

Group 2 - Dana group - (DMC): 50 patients will be included in the study. Group 3 - Schneider group - (ShMC): 50 patients will be included in the study. Group 4 - Detroit group - (WYUMC): 100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).

Patients with Sickle cell hemoglobin C (SC) and Sickle cell hemoglobin D (SD) disease will not be included as part of the study analysis due to the small numbers of patients expected, but the investigators are encouraged to report the data of those patients for further analysis.

Age: No age limits, patients can be included since diagnosis till age 40 since teenagers and young adults are often treated at pediatric hematology units.

Gender: Males and Females will be included in the study. Pregnant patients: Pregnancy will not be considered as exclusion criteria. Data about pregnancy under Hydroxyurea treatment both in females and in males should be included, including malformations in the offspring. It needs to be emphasized that the recommendation to the patients in both sexes is to stop Hydroxyurea treatment at last three months before conception.

Data collection: Data will be collected from the medical files. Demographic and family history and laboratory findings at diagnosis will be included.

Genetic mutations of the β globin gene in patients with Sickle Cell β thalassemia will be included if previously analyzed and recorded in medical files. Also α globin mutations and SCA haplotypes will be included if they were previously analyzed and are part of the data already present in the medical files.

Further genetic analysis including β and α globin mutations, haplotypes and xmn1 polymorphism will be included in an extension study but those analysis are not an integral part of this initial study unless they were performed before this present study.

Clinical complaints from the last 10 years will be summarized. Iron chelation and Hydroxyurea treatment given in the last 10 years will be summarized.

Complications that were diagnosed at any age will also be recorded.

Exclusion criteria:

• Patients without sufficient data at the medical files due to lack of regular follow up will be excluded.
• Patients that give explicit refuse in participation.

Inclusion criteria:

• All the patients currently treated and followed up at the centers in Israel will be included.
• A similar number of patients at same age range and same diagnosis will be included from the whole cohort at Detroit MC. Since at Detroit MC a significant larger number of patients, the criteria for patient's selection at this center will be a cohort matched for gender and age to the Israel patients.

Enrollment: 300 estimated patients

Sex: All

Ages: 1 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients followed up in the centers that participate in the study.
• Pregnancy will not be considered as exclusion criteria.

Exclusion criteria

• Patients with SC and SD disease will not be included.

Trial design

300 participants in 4 patient groups

Group 2 - Dana group

Description:

50 patients will be included in the study.

Group 3 - Schneider group

Description:

50 patients will be included in the study

Group 4 - Detroit group

Description:

100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).

Group 1 - Emek group

Description:

100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).